INKT MiNK Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why INKT matters now
MiNK Therapeutics, Inc. (INKT) is a US stock in Healthcare. The latest InvestLog snapshot shows $11.05 with -3.58% on the session and $55.0M in market capitalization; recent performance reads 1-month +17.29% and YTD +8.88%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-2.7M, and EPS of $-0.57. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -10.4%.
The latest indexable market news headline is "MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $35.00; recent insider activity includes Ryan Barbara filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-4.59
P/S
0.00
EV/EBITDA
-4.14
DCF Value
$1.16
FCF Yield
-10.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
76.0%
ROA
-120.2%
ROIC
-415.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-2.7M | $-0.57 |
| Q4 2025 | $0.00 | $-2.6M | $-0.55 |
| FY 2025 | $0.00 | $-12.5M | $-2.93 |
| Q3 2025 | $0.00 | $-2.9M | $-0.65 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$35.00
Target (Median)
$35.00
Target Range
$35.00 - $35.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.47
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.